65,437 trials
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving an American College of Rheumatology (ACR) 20 Response at Week 12 — 44.2; 56.1; 63.5; 68.6 percentage of participants — p=0.1236
Thoracic Diseases
Primary: Number of Subjects With Procedural Technical Success — 123 Participants
Patient Reported Outcomes
Primary: Rates of UCC Visits and Readmissions Between the Team Monitoring and Enhanced Feedback Cohorts up to 30 Days Post-operatively — 31; 38; 44; 60 Participants
Acne Vulgaris
Primary: Change in HPA Axis Response to Cosyntropin — 17.0; 16.8; 27.7; 24.6 mcg/dL
Residual Disease · Aggressive Periodontitis
Primary: Clinical Attachment Level at Baseline, 3 Months and 6 Months — 5.5; 5.29; 4.64; 4.73 mm
Colorectal Cancer
Primary: Overall Survival（OS） — 7.8; 7.1 Months — p=0.035
Macular Edema
Primary: Average Change From Baseline (CFB) in Best Corrected Visual Acuity (BCVA) in the Study Eye — 1.4; 4.3 letters — p=0.0011
Body Fat Disorder
Primary: Proportion of Pre-treatment Images Correctly Identified — 32 photos
Pain
Primary: Number of Participants Achieving Pulpal Anesthesia Success. — 44; 40 Participants — p=1.00
Schizophrenia
Primary: Time to First Hospitalization — 530.6; 613.7 days
Advanced Biliary Tract Carcinoma
Primary: MTD of MEK162 - Phase I — 45 mg
HCV Coinfection · Liver Disease · HIV
Primary: Total Number of HCV-infected Hepatocytes Measured in Liver Tissue Obtained by Liver Biopsy at Day 0 (Pre-treatment) and at Day 7 of Antiviral Therapy — 45; 16; 290; 2…
Hepatitis C Virus
Primary: Pharmacokinetic (PK) Parameter of Velpatasvir: AUClast — 5597.8; 7971.7 h*ng/mL
Irritable Bowel Syndrome Characterized by Constipation
Primary: Overall Change From Baseline in Abdominal Score (Abdominal Bloating, Abdominal Discomfort, and Abdominal Pain) Throughout the Treatment Period — -1.182; -1.898 score on…
Blood Pressure
Primary: Comparative Performance of Clinic, Home, and Kiosk — -4.7; -0.1; 9.5; -7.2 millimeters of mercury — p=<0.05